NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
11 trialsNCT06614140 2024-09-26
Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Active not recruiting
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed
NCT03380871 2021-02-26
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
BioNTech SE
Phase 1 Completed
NCT02897765 2021-02-25
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech SE
Phase 1 Completed
NCT03162562 2020-12-22
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
CanariaBio Inc.
Phase 1 Terminated
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT03597282 2020-09-03
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT02413827 2017-04-07
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Celldex Therapeutics
Phase 1/2 Terminated
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed